ACRX
Income statement / Annual
Last year (2023), AcelRx Pharmaceuticals, Inc.'s total revenue was $651,000.00,
a decrease of 63.24% from the previous year.
In 2023, AcelRx Pharmaceuticals, Inc.'s net income was -$10.29 M.
See AcelRx Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$651,000.00
|
$1.77 M
|
$2.82 M
|
$5.42 M
|
$2.29 M
|
$2.15 M
|
$8.00 M
|
$17.36 M
|
$19.26 M
|
$5.22 M
|
| Cost of Revenue |
$0.00 |
$2.59 M |
$3.75 M |
$6.03 M |
$6.81 M |
$3.98 M |
$10.66 M |
$12.32 M |
$1.77 M |
$0.00 |
| Gross Profit |
$651,000.00 |
-$820,000.00 |
-$935,000.00 |
-$616,000.00 |
-$4.52 M |
-$1.83 M |
-$2.66 M |
$5.04 M |
$17.49 M |
$5.22 M |
| Gross Profit Ratio |
1 |
-0.46 |
-0.33 |
-0.11 |
-1.97 |
-0.85 |
-0.33 |
0.29 |
0.91 |
1 |
| Research and Development
Expenses |
$5.55 M
|
$5.19 M
|
$4.10 M
|
$4.02 M
|
$4.66 M
|
$13.14 M
|
$19.41 M
|
$21.40 M
|
$22.49 M
|
$24.52 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$43.93 M
|
$20.77 M
|
$16.61 M
|
$15.60 M
|
$14.20 M
|
$18.35 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.99 M
|
$25.67 M
|
$30.94 M
|
$36.33 M
|
$45.03 M
|
$20.77 M
|
$16.61 M
|
$15.60 M
|
$14.20 M
|
$18.35 M
|
| Other Expenses |
$0.00 |
$84.05 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.53 M |
$0.00 |
| Operating Expenses |
$17.54 M |
$30.87 M |
$35.03 M |
$40.35 M |
$49.69 M |
$33.90 M |
$36.02 M |
$37.00 M |
$36.69 M |
$42.87 M |
| Cost And Expenses |
$17.54 M |
$33.46 M |
$38.78 M |
$46.38 M |
$56.49 M |
$37.88 M |
$46.68 M |
$49.31 M |
$38.46 M |
$42.87 M |
| Interest Income |
$6.74 M |
$1.50 M |
$3.16 M |
$3.89 M |
$2.17 M |
$1.14 M |
$510,000.00 |
$918,000.00 |
$1.72 M |
$6.94 M |
| Interest Expense |
$134,000.00 |
$1.15 M |
$2.29 M |
$3.31 M |
$1.20 M |
$12.56 M |
$14.04 M |
$12.15 M |
$5.41 M |
$2.64 M |
| Depreciation &
Amortization |
$311,000.00
|
$6.45 M
|
$5.14 M
|
$3.89 M
|
$2.17 M
|
$575,000.00
|
$1.74 M
|
$2.05 M
|
$1.98 M
|
$866,000.00
|
| EBITDA |
-$16.89 M
|
-$30.18 M
|
-$30.83 M
|
-$37.07 M
|
-$52.04 M
|
-$34.59 M
|
-$36.43 M
|
-$28.99 M
|
-$15.49 M
|
-$29.85 M
|
| EBITDA Ratio |
-25.94 |
-17.04 |
-10.94 |
-6.84 |
-22.73 |
-16.08 |
-4.56 |
-1.67 |
-0.8 |
-5.72 |
| Operating Income Ratio
|
-25.94
|
-20.68
|
-12.76
|
-7.56
|
-23.68
|
-16.61
|
-4.84
|
-1.84
|
-1.04
|
-7.22
|
| Total Other
Income/Expenses Net |
$6.60 M
|
$79.49 M
|
$871,000.00
|
$588,000.00
|
$968,000.00
|
-$11.42 M
|
-$13.53 M
|
-$11.23 M
|
-$3.69 M
|
$4.30 M
|
| Income Before Tax |
-$10.29 M |
$47.77 M |
-$35.09 M |
-$40.38 M |
-$53.24 M |
-$47.15 M |
-$52.21 M |
-$43.19 M |
-$23.64 M |
-$33.35 M |
| Income Before Tax Ratio
|
-15.8
|
26.97
|
-12.45
|
-7.45
|
-23.26
|
-21.92
|
-6.53
|
-2.49
|
-1.23
|
-6.39
|
| Income Tax Expense |
$0.00 |
$13,000.00 |
$5,000.00 |
$4,000.00 |
$3,000.00 |
$2,000.00 |
-$701,000.00 |
-$34,000.00 |
$760,000.00 |
$6.94 M |
| Net Income |
-$10.29 M |
$47.76 M |
-$35.10 M |
-$40.38 M |
-$53.24 M |
-$47.15 M |
-$51.51 M |
-$43.16 M |
-$24.40 M |
-$33.35 M |
| Net Income Ratio |
-15.8 |
26.96 |
-12.46 |
-7.46 |
-23.26 |
-21.92 |
-6.44 |
-2.49 |
-1.27 |
-6.39 |
| EPS |
-0.0007 |
5.73 |
-5.86 |
-9.47 |
-13.45 |
-16.14 |
-21.97 |
-19.05 |
-11.02 |
-15.36 |
| EPS Diluted |
-0.0007 |
5.72 |
-5.86 |
-9.47 |
-13.45 |
-16.14 |
-21.97 |
-19.05 |
-10.97 |
-15.05 |
| Weighted Average Shares
Out |
$14.26 B
|
$7.39 M
|
$5.99 M
|
$4.26 M
|
$3.96 M
|
$2.92 M
|
$2.34 M
|
$2.27 M
|
$2.22 M
|
$2.17 M
|
| Weighted Average Shares
Out Diluted |
$14.26 B
|
$7.41 M
|
$5.99 M
|
$4.26 M
|
$3.96 M
|
$2.92 M
|
$2.34 M
|
$2.27 M
|
$2.22 M
|
$2.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
